Novo Nordisk A/S (NYSE:NVO) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,167,683 shares of the company's stock after selling 110,977 shares during the quarter. Envestnet Asset Management Inc. owned 0.09% of Novo Nordisk A/S worth $358,504,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Victory Capital Management Inc. grew its stake in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock worth $5,482,000 after buying an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC raised its stake in Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after acquiring an additional 30,420 shares during the last quarter. Versant Capital Management Inc acquired a new position in Novo Nordisk A/S in the 4th quarter worth approximately $86,000. Finally, Talbot Financial LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $4,066,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 5.8 %

Shares of NYSE NVO traded up $3.56 during midday trading on Wednesday, hitting $65.16. The company's stock had a trading volume of 13,222,250 shares, compared to its average volume of 5,739,661. The business's fifty day simple moving average is $78.66 and its two-hundred day simple moving average is $94.43. The firm has a market capitalization of $292.41 billion, a price-to-earnings ratio of 19.81, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 1 year low of $59.52 and a 1 year high of $148.15.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were paid a $0.7874 dividend. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is currently 49.54%.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent research reports. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, December 23rd. Finally, StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Monday. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.